Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension

Critical Care Medicine

Volumn 30, Issue 11, 2002, Pages 2489-2492

  Ghofrani, Hossein A ^a   Rose, Frank ^a   Schermuly, Ralph T ^a   Olschewski, Horst ^a   Wiedemann, Ralph ^a   Weissmann, Norbert ^a   Schudt, Christian ^a   Tenor, Herrmann ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a  

^a Department of Internal Medicine ^*  (Germany)

Author keywords

Aerosol; Iloprost; Phosphodiesterase inhibition; Prostanoids; Pulmonary hypertension; Tolafentrine

Indexed keywords

ILOPROST; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; TOLAFENTRINE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CALCINOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME INHIBITION; ESOPHAGUS DISEASE; FEMALE; HEART CATHETERIZATION; HEMODYNAMIC MONITORING; HUMAN; LUNG BLOOD VESSEL; LUNG GAS EXCHANGE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SIDE EFFECT; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; TELANGIECTASIA; VASODILATATION;

EID: 0036852964     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200211000-00014     Document Type: Article

References (10)

1. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The primary pulmonary hypertension study group [see comments]. N Engl J Med 1996; 334:296-302
2. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al: Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-1174
3. Olschewski H, Walmrath D, Schermuly R, et al: Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-824
4. Walmrath D, Schneider T, Pilch J, et al: Effects of aerosolized prostacyclin in severe pneumonia: Impact of fibrosis. Am J Respir Crit Care Med 1995; 151(3 Pt 1):724-730
5. Olschewski H, Ghofrani HA, Schmehl T, et al: Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial. Ann Intern Med 2000; 132:435-443
6. Hoeper MM, Schwarze M, Ehlerding S, et al: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
7. Gessler T, Schmehl T, Hoeper MM, et al: Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001; 17:14-19
8. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75:725-48
9. Schermuly RT, Ghofrani HA, Enke B, et al: Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999; 160(5 Pt 1):1500-1506
10. Schermuly RT, Roehl A, Weissmann N, et al: Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000; 292:512-520